The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-13 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Microfilament networks – Animal cells commonly have a cell cortex under the cell membrane that contains a large number of actin filaments, which precludes the presence of organelles. This network is connected with numerous receptors that relay signals to the outside of a cell.
Pheromone Endorphins Anaphrodisiac Date rape drug Entactogen Food and sexuality Fork Me, Spoon Me, 2006 book Hypersexuality Hypoactive sexual desire disorder List of investigational sexual dysfunction drugs Love potion Phytoestrogen Phytoandrogen Androgens Estrogens Viagra Vyleesi
== Antibody vulnerability period in children == The period following birth is critical for the development of a child's immune system. Initially, a newborn relies heavily on passive immunity transferred from the mother, primarily through the placenta and breastfeeding. As breastfeeding frequency declines, immune protection gradually wanes, making the child more vulnerable and increasingly reliant on their developing immune system. This transitional phase, known as the "antibody vulnerability period", lasts until approximately three to four years of age, during which the child's immune system matures and becomes fully functional. To combat pathogens, babies need to develop their own specific antibodies recognizing these antigens. And these types of antibodies are known as immunoglobulins. Immunoglobulin G (IgG) is one of them. Babies are unable to make their own IgG antibodies at birth and rely on maternal transfer of IgG via the placenta during the third trimester. Other types of immunoglobulins (IgA, IgM, IgE, and IgD) do not cross the placenta. It is believed that IgG is important in protecting babies against infections. Naturally bioactive Immunoglobulin G is found in breast milk, which plays a significant role in early life during the vulnerable period. The Y-shaped structure of Immunoglobulin G allows it to effectively identify and combat pathogens, providing antibody-like protection to the child. Research indicates that maintaining adequate IgG levels during early childhood may help mitigate the risks associated with this immune vulnerability.
When gunfights finally erupted outside and around the television studio, they were almost always the result of miscommunication. One such example is when a group of Patriotic Guardsmen took up a defensive position in a building close to the television centre on the 23rd. It has not been established who took the first shots at around 17:00, but a gunfight soon ensued with those in the television station returning fire onto the position of the Patriotic guards, according to an aid worker who had set up a first aid station at the side of the television station, and who said that, afterwards, the group of Patriotic Guardsmen would later deny that they had fired first. This is only one of many examples of gunfights between pro-revolution forces after the flight of Ceaușescu on the 22nd. Scenes of major gunfights during this period include the television, radio and telephone buildings, as well as Casa Scânteii (the nation's print media center, which serves a similar role today under the name of the "House of the Free Press", Casa Presei Libere) and the post office in the district of Drumul Taberei; Palace Square (site of the Central Committee building, but also of the Central University Library, the national art museum in the former Royal Palace, and the Ateneul Român (Romanian Athenaeum), Bucharest's leading concert hall); the university and the adjoining University Square (one of the city's main intersections); Otopeni and Băneasa airports; hospitals; and the Ministry of Defence.
In humans, glucose is metabolized by glycolysis and the pentose phosphate pathway. Glycolysis is used by all living organisms, with small variations, and all organisms generate energy from the breakdown of monosaccharides. In the further course of the metabolism, it can be completely degraded via oxidative decarboxylation, the citric acid cycle (synonym Krebs cycle) and the respiratory chain to water and carbon dioxide. If there is not enough oxygen available for this, the glucose degradation in animals occurs anaerobic to lactate via lactic acid fermentation and releases much less energy. Muscular lactate enters the liver through the bloodstream in mammals, where gluconeogenesis occurs (Cori cycle). With a high supply of glucose, the metabolite acetyl-CoA from the Krebs cycle can also be used for fatty acid synthesis. Glucose is also used to replenish the body's glycogen stores, which are mainly found in liver and skeletal muscle. These processes are hormonally regulated. In other living organisms, other forms of fermentation can occur. The bacterium Escherichia coli can grow on nutrient media containing glucose as the sole carbon source. In some bacteria and, in modified form, also in archaea, glucose is degraded via the Entner-Doudoroff pathway. With glucose, a mechanism for gene regulation was discovered in E. coli, the catabolite repression (formerly known as glucose effect). Use of glucose as an energy source in cells is by either aerobic respiration, anaerobic respiration, or fermentation.
Sources: en.wikipedia.org
These findings provide a possible explanation for how some studies found antiproliferative and atrophic changes in the endometrium with transdermal progesterone. However, elevated levels of progesterone in the endometrium with transdermal progesterone have yet to be demonstrated. Concern has been raised regarding transdermal progesterone in that the effects of such supraphysiological levels of progesterone in tissues are unknown and hence the potential for adverse effects has not been ruled out. Salivary monitoring of progesterone levels in women using transdermal progesterone and adjustment of dosage as necessary has been suggested as a possible means to help prevent potential adverse effects. The mechanism by which transdermal progesterone in cream and water-based gel produces very high salivary and capillary blood levels in spite of low circulating levels is not well-understood. However, at least two hypotheses have been proposed. Steroid hormones including progesterone have been found to be transported by red blood cells in addition to serum carrier proteins like albumin, sex hormone-binding globulin, and corticosteroid-binding globulin, and as much as 15 to 35% of total steroid hormone content in whole blood may be confined to red blood cells. According to the hypothesis, very high local concentrations of progesterone occur in skin capillaries after transdermal application and are taken up by red blood cells.
=== 2 May === The SAF retook the villages of Al-Sufi, Al-Alqa and Al-Shaqeeq on the west bank of the White Nile in White Nile State, while the RSF launched a drone attack on the headquarters of the SAF's 18th Infantry Division in Kosti.
=== Adults === The widely used rule calculating normal maximum ESR values in adults (98% confidence limit) is given by a formula devised in 1983 from a study of ≈1000 individuals over the age of 20: The normal values of ESR in men is age (in years) divided by 2; for women, the normal value is age (in years) plus 10, divided by 2.
==== Azapirones (serotonin 5-HT1A receptor agonists) ==== Buspirone (Buspar) – serotonin 5-HT1A receptor partial agonist and other actions Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor partial agonist [42]
CEEs are prodrugs of the active forms of the estrogens. Sodium estrone sulfate is a prodrug of estrone, which in turn is a prodrug of estradiol, while sodium equilin sulfate is a prodrug of equilin and then of 17β-dihydroequilin. As such, the major active estrogens with CEEs are estradiol and 17β-dihydroequilin, which have potent estrogenic activity and account for most of the effects of CEEs. The 17α-estrogens in CEEs such as 17α-estradiol and 17α-dihydroequilin have low estrogenicity and are thought to contribute minimally to its effects. There are many different steroids in natural CEE products like Premarin, as many as 230 compounds and including even androgens and progestogens, but only the estrogens are present in sufficient amounts to produce clinically-relevant effects. A dosage of 0.625 mg/day oral CEEs has been found to increase SHBG levels by 100%. For comparison, 1 mg/day oral estradiol increased SHBG levels by 45%, while 50 μg/day transdermal estradiol increased SHBG levels by 12%. Ethinylestradiol is more potent in its effects on liver protein synthesis than either CEEs or estradiol, with 10 μg/day oral ethinylestradiol having been found to be approximately equivalent to 1.25 mg/day CEEs.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.